Fulphila is paid 72.2% below Neulasta
6 biosimilars bill against Neulasta (J2506). On average they are paid ↓ 26.6% relative to the reference product per 0.5 MG in 4Q26.
- Neulasta (reference)
- Fulphila
- Fylnetra
- Udenyca
- Nyvepria
- Stimufend
- Ziextenzo
AfliberceptBevacizumabDenosumabEculizumabEpoetin alfaFilgrastimInfliximabNatalizumabPegfilgrastimRanibizumabRituximabTocilizumabTrastuzumabUstekinumab
All products
| Product | Code | CMS description | Per 0.5 MG | vs. reference | CMS 8% add-on note | 8 quarters |
|---|---|---|---|---|---|---|
| Neulasta | J2506 | Inj pegfilgrast ex bio 0.5mg | $201.241 | Reference | – | |
| Fulphila | Q5108 | Injection, fulphila | $55.964 | ↓ 72.2% | Yes | |
| Fylnetra | Q5130 | Inj, fylnetra, 0.5 mg | $94.292 | ↓ 53.1% | Yes | |
| Udenyca | Q5111 | Injection, udenyca 0.5 mg | $128.967 | ↓ 35.9% | No | |
| Nyvepria | Q5122 | Inj, nyvepria | $141.289 | ↓ 29.8% | Yes | |
| Stimufend | Q5127 | Inj, stimufend, 0.5 mg | $163.948 | ↓ 18.5% | Yes | |
| Ziextenzo | Q5120 | Inj pegfilgrastim-bmez 0.5mg | $302.247 | ↑ 50.2% | No |
Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.